SciELO - Scientific Electronic Library Online

 
vol.73 número5SÍNDROME HELLP: EXPERIENCIA DEL HOSPITAL REGIONAL DE PUERTO MONTT, 2000-2006LONGITUD DEL CANAL CERVICAL UTERINO COMO FACTOR DE RIESGO DE PARTO PREMATURO EN PACIENTES SINTOMÁTICAS índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista chilena de obstetricia y ginecología

versión impresa ISSN 0048-766Xversión On-line ISSN 0717-7526

Resumen

NAZZAL N, Omar et al. IMIQUIMOD EN CREMA AL 5% EN EL TRATAMIENTO DE VERRUGAS ANOGENITALES ASOCIADAS A VPH: EXPERIENCIA PRELIMINAR. Rev. chil. obstet. ginecol. [online]. 2008, vol.73, n.5, pp.325-329. ISSN 0048-766X.  http://dx.doi.org/10.4067/S0717-75262008000500008.

Background: The chronic infection by high-risk HPV serotypes is bly associated with cervical cáncer, detection of HPV on tissue sample has been reported 99.7% of cases. The anal-genital warts represent the clinical manifestation of the persistent infection by this virus. Objectives: To investígate the efficacy and safe-ty of Imiquimod cream 5% concentration, in the treatment of anal-genital warts in women. Methods: A non-randomized prospective study in women diagnosed with anal-genital warts HPV associated. The treatment consists in self-application of imiquimod cream 5%, three times a week for a period of 16 weeks or more. We define complete response to treatment in those patients where the lesión disappeared completely, and partial response to those where the lesión declined at least 50% of its initial volume. Results: Over a period of 8 months were admitted to the study and treated a total of 38 patients. Treatment duration varied bet-ween 1 and 4 months. The average number of applications was 28.7 times. 66% (25 cases) of the patients had a complete response, in three cases there was no response, one of them was an immunodepressed patients, in 10 cases there was partial response. The patients with complete response needed an average of 28.7 applications to get that result. Conclusions: Imiquimod is a drug with high effectiveness and safety in the treatment of anal-genital warts HPV associated, in a three times per week and at least 10 weeks total duration treatment.

Palabras clave : Human papillomavirus; anal-genital warts; imiquimod; immunomodulation; self-aplication.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons